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Abstract
Background: Examination of factors associated with late stage diagnosis of breast cancer is useful to identify
areas which are amenable to intervention. This study analyses trends in cancer stage at diagnosis and impact of
socio-demographic, cancer biological and screening characteristics on cancer stage in a population-based series
of women with invasive breast cancer in New Zealand.
Methods: All women diagnosed with invasive breast cancer between 2000 and 2013 were identified from two
regional breast cancer registries. Factors associated with advanced (stages III and IV) and metastatic (stage IV)
cancer at diagnosis were analysed in univariate and multivariate models adjusting for covariates.
Results: Of the 12390 women included in this study 2448 (19.7 %) were advanced and 575 (4.6 %) were metastatic at
diagnosis. Māori (OR = 1.86, 1.39-2.49) and Pacific (OR = 2.81, 2.03-3.87) compared with NZ European ethnicity, other
urban (OR = 2.00, 1.37-2.92) compared with main urban residency and non-screen (OR = 6.03, 4.41-8.24) compared
with screen detection were significantly associated with metastatic cancer at diagnosis in multivariate analysis. A steady
increase in the rate of metastatic cancer was seen which has increased from 3.8 % during 2000-2003 to 5.0 % during
2010-2013 period (p = 0.042).
Conclusions: Providing equitable high quality primary care and increasing mammographic screening coverage needs
to be looked at as possible avenues to reduce late-stage cancer at diagnosis and to reduce ethnic, socioeconomic and
geographical disparities in stage of breast cancer at diagnosis in New Zealand.
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Background
Breast cancer is the commonest cause of cancer in New
Zealand women (excluding non-melanoma skin cancer)
and accounts for approximately 3000 diagnoses and 600
deaths per year [1]. One of the most important factors
in predicting survival from breast cancer is the stage at
diagnosis. Women with early stage disease have an ex-
cellent prognosis while those with metastatic disease at
diagnosis have a 5-year survival of around 20 % [2].
Stage at diagnosis can be influenced by the diagnostic
pathway and the characteristics of the tumour [3]. The
diagnostic pathway is important – population based
screening with mammography has been shown to in-
crease the proportion of women diagnosed with early
breast cancer [4].
In New Zealand, late diagnosis with advanced or meta-
static disease has been associated with Māori ethnicity
and social deprivation [5]. Differences by ethnicity and
social deprivation have important associations in other
countries [6–9], while in some countries it has been
shown that women living outside main urban areas are
more likely to be diagnosed with advanced disease [10].
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The reason why women from certain demographic groups
may present late may be due to factors related to the
women e.g. health literacy, psychosocial factors, etc., [11]
or system issues causing diagnostic delays such as a short-
age of primary care physicians [12] and difficulty accessing
diagnostic facilities [13]. Furthermore, community-level
determinants which include health policy, health care de-
livery system, and community risk factors have also been
observed to be contributing to socioeconomic and geo-
graphic variations in breast cancer stage at diagnosis [14].
Another cause of advanced stage at diagnosis may be the
biology of the cancer – some types of cancer are more
aggressive and are more likely to metastasize early [15].
It is important when looking at a population of women
with breast cancer to examine the associations with late
diagnosis to identify which factors may be amenable to
intervention. This study assesses the importance of
socio-demographic factors, breast cancer screening and
biological factors in explaining differences in cancer
stage at diagnosis in a population-based series of female




Data were obtained from the Auckland (ABCR) and
Waikato Breast Cancer Registries (WBCR), which are
prospective population based databases that capture al-
most 100 % of the newly diagnosed breast cancers in the
respective regions since 2000. These two registries cover
an area that includes over 40 % of the total New Zealand
population. In general, this population resembles average
New Zealand population in terms of ethnicity, socioeco-
nomic status and urban/rural residential distribution.
Completeness and accuracy of the data included in these
registries have been validated previously [16, 17]. Data
from the two registries were linked with the New Zealand
Cancer Registry (NZCR) and the National Mortality
Collection (NMC).
Study population
All women with primary breast cancer diagnosed over a
13-year period between 01/06/2000 and 31/05/2013
were identified from the two registries. This included a
total of 14469 breast cancers [12390 (85.6 %) invasive
and 2079 (14.4 %) in situ cancers]. Of this 12390 women
with invasive, primary breast cancer were included in
the analyses.
Healthcare system in New Zealand
New Zealand has a publicly funded national health system
that provides specialist and hospital care to all citizens
without patient charges. Parallel to the public system,
there are a variety of private hospital facilities available,
which are mostly funded through insurance schemes.
The primary health care system in New Zealand is
highly subsidized, but patient co-payment is also sub-
stantial. For instance, a visit to a general practitioner
on average may cost between NZ$20 and NZ$50 for an
adult. A national breast cancer screening programme,
BreastScreen Aotearoa provides free biannual breast
cancer screening for all women aged 45–69 years, and
has operated since 1999.
Study covariates
Patient ethnicity was identified from the breast cancer
registries or where it was not available from these registries
it was obtained from the NZCR or the NMC, as per the
Ministry of Health ethnicity data protocols [18]. Ethnicity
was categorized into NZ European, Māori, Pacific, Asian
and Other. Socioeconomic deprivation was classified ac-
cording to the New Zealand Deprivation Index 2006
(NZDep2006) [19]. The NZDep2006 assigns small residen-
tial areas a deprivation decile on a scale of 1 to 10 based
on nine socio-economic variables measured during the
2006 population census; decile1-least deprived, decile10-
most deprived. Urban/rural residential status of each
woman was categorized into main urban, other urban (in-
dependent or satellite urban) and rural based on the New
Zealand Statistics urban/rural classification system [20].
These variables were selected on the basis of theoretical
relevance and empirical evidence of their utility in asses-
sing the impact of socio-demographic factors on a variety
of health outcomes including cancer [21]. Cancer stage at
diagnosis was defined according to the Tumour, Node, and
Metastasis (TNM) system [22] and was categorized into
early (TNM stage groups I and II), advanced (stage groups
III and IV) and metastatic (stage group IV) for analysis. In-
vasive tumour grade was defined according to the Elston
and Ellis modified Scarff-Bloom-Richardson breast cancer
grading system [23]. Oestrogen (ER) and progesterone
(PR) receptor status was determined based on the results
of immunohistochemistry tests and classified as positive or
negative. HER-2 status was based on Fluorescent In-Situ
Hybridization (FISH) test or when this was not available,
on immunohistochemistry [24].
Statistical analysis
Univariate differences in distribution of factors among
groups of interest were tested by using Chi squared (χ²)
test for trend or by linear-by-linear association test [25].
Unconditional logistic regression models were used to
estimate the contribution of covariates towards advanced
or metastatic cancer at diagnosis in multivariate ana-
lyses. All statistical analyses were performed in SPSS
(Version 22) (18).
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Ethics approval
Both ABCR and WBCR function with ethics approval
from the New Zealand Northern ‘A’ Health and Disabil-
ity Ethics Committee. This required individual patient
consent from patients for their data to be included.
Since 2012, the consent process was waived off by the
same ethics committee as it was noted that for data from
these registries to be more useful at a national level all
patients with breast cancer are needed to be included.
Additionally ethical approval for this study was obtained
from the same New Zealand Northern ‘A’ Health and
Disability Ethics Committee (Ref. No. 12/NTA/42).
Results
Of the 12390 women included in this study 9630
(77.7 %) were from the Auckland Region and 2755
(22.3 %) from the Waikato. The mean age of the popula-
tion was 57 years. 8972 (73.3 %) were NZ European,
1162 (9.5 %) were Māori, 809 (6.6 %) were Pacific, 984
(8 %) Asian and 311 (2.5 %) belonged to Other ethnic
groups. Ethnicity data were unavailable for 152 (1.2 %)
women. Māori, Pacific and Asian women were signifi-
cantly younger than the NZ European women, in keep-
ing with the younger age structure of Māori, Pacific and
Asian populations in New Zealand [26]. Staging data
were missing for 5 (0.04 %) while tumour grade was
missing for 5.5 % of study women. Information on hor-
mone receptor status was not available for 2.4 % of the
study population. HER-2 status was not available for
23.2 % of the women, a majority (84.2 %) of whom were
diagnosed with breast cancer prior to 2006.
Distribution of socio-demographic and tumour charac-
teristics by stage at diagnosis are summarized in Table 1.
Proportion of metastatic disease have increased from
3.8 % to 5.0 % over the study period while the rate of stage
I cancers has increased from 42.2 % to 45.6 %. A corre-
sponding reduction was seen for rates of stage II and III
cancers (from 38.0 % to 35.9 % and 15.7 % to 13.6 %, re-
spectively). Age younger than 40 and older than 70 years
were significantly associated with advanced and metastatic
breast cancer at diagnosis compared with women aged be-
tween 40 to 69 years, a majority of whom are within the
breast cancer screening age. NZ European and Asian
women tended to be diagnosed at an earlier stage, com-
pared with Māori and Pacific women. Māori and Pacific
women were around two and three times more likely
respectively, to be diagnosed with metastatic disease com-
pared with NZ European women (3.9 % vs. 7.6 % and
10.9 %, respectively). Over a third (33.7 %) of the cancers
in Pacific women and a quarter of the cancers in Māori
(26.1 %) were advanced (stage III or IV) at diagnosis com-
pared with less than a fifth in NZ European (18.3 %) and
Asian (17.7 %) women.
Significantly higher proportions of more advanced can-
cer, including metastatic cancer were observed in women
from high deprivation compared with low deprivation
groups and rural compared with urban residing women
(Table 1). Proportions of advanced and metastatic cancer
were observed to be higher in the Waikato (21.7 % and
5.9 %, respectively) compared with Auckland (19.2 % and
4.3 %, respectively). Further, a greater increase in the pro-
portion of metastatic cancer was observed in the Waikato
region (58 %) compared with Auckland (17 %) over the
study period. Significantly higher proportions of advanced
cancer were seen in non-screen compared with screen de-
tected women and in women receiving treatment from
public compared with non-public hospitals. Greater pro-
portions of cancers with adverse prognostic characteristics
including higher grade, oestrogen (ER) and progesterone
receptor (PR) negativity and human epidermal growth fac-
tor type-2 (HER-2) positivity were advanced or metastatic
at diagnosis compared with lower grade, ER/PR positive
and HER-2 negative cancers, respectively.
Multivariate logistic regression models were used to
assess the importance of study variables in explaining
advanced and metastatic cancer at diagnosis and are
shown in Table 2. Patients for whom information on
tumour stage (n = 5) were not available were excluded
from regression analyses. Advanced cancer at diagnosis
was significantly associated with Māori [Odds ratio (OR
= 1.27, 1.08–1.49)] and Pacific (OR = 1.72, 1.43–2.06)
compared with NZ European ethnicity, higher socioeco-
nomic deprivation (p < 0.001) and non-screen compared
with screen detection (OR = 3.79, 3.33–4.34).
Odds ratios for metastatic compared with early stage
(i.e., stages I and II) cancer were significantly elevated
for Māori (OR = 1.86, 1.39–2.49) and Pacific (OR = 2.81,
2.03–3.87) women, but not for Asian (OR = 0.90, 0.61–
1.33) or Other (OR = 1.56, 0.86–2.83) women, relative to
NZ European women (Table 2). Non-screen compared
with screen detection (OR = 6.03, 4.41–8.24), other urban
compared with main urban residency (OR = 2.00,
1.37–2.92), higher socioeconomic deprivation and later
year of diagnosis were also significantly associated with
metastatic cancer at diagnosis.
Associations between stage at diagnosis and, ethnicity
and sociodemographic factors were additionally analysed
by year category to identify trends over time (data not
shown). However, no significant differences in these as-
sociations were observed by year category. As socioeco-
nomic and geographic variables included missing data,
regression analysis was repeated using only cases with
complete data for all variables. The results were almost
identical to the full dataset regression model, and are
not presented in this report. Imputation of missing
values was not undertaken due to the similarity of these
results.
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Table 1 Distribution of selected characteristics by percentage among 12,390 female breast cancer patients diagnosed in New
Zealand during 2000–2013
Characteristic Stage I Stage II Stage III Stage IV Total
n % n % n % n % p n %
5362 43.3 % 4575 36.9 % 1873 15.1 % 575 4.6 % 12385 100.0 %
Age
<40 204 25.4 % 333 41.5 % 218 27.1 % 48 6.0 % <0.001 803 6.5 %
40–49 1053 39.2 % 1029 38.3 % 492 18.3 % 114 4.2 % 2688 21.7 %
50–59 1603 47.8 % 1144 34.1 % 485 14.5 % 122 3.6 % 3354 27.1 %
60–69 1579 55.2 % 866 30.3 % 311 10.9 % 105 3.7 % 2861 23.1 %
70–79 606 38.7 % 652 41.7 % 202 12.9 % 104 6.6 % 1564 12.6 %
80+ 317 28.4 % 551 49.4 % 165 14.8 % 82 7.4 % 1115 9.0 %
Ethnicity
NZ European 4024 44.9 % 3302 36.8 % 1291 14.4 % 351 3.9 % <0.001 8968 73.3 %
Māori 430 37.0 % 428 36.8 % 216 18.6 % 88 7.6 % 1162 9.5 %
Pacific 217 26.8 % 319 39.4 % 186 23.0 % 87 10.8 % 809 6.6 %
Asian 439 44.7 % 370 37.6 % 140 14.2 % 34 3.5 % 983 8.0 %
Other 161 51.8 % 105 33.8 % 31 10.0 % 14 4.5 % 311 2.5 %
Unknown 91 51 9 1 152 (1.2 %)
Menopausal status
Pre 1291 36.1 % 1402 39.2 % 738 20.6 % 150 4.2 % <0.001 3581 29.9 %
Peri 288 45.2 % 239 37.5 % 93 14.6 % 17 2.7 % 637 5.3 %
Post 3554 45.8 % 2821 36.4 % 998 12.9 % 385 5.0 % 7758 64.8 %
Unknown 221 111 44 23 399 (3.2 %)
Year of diagnosis
2000–2003 1262 42.4 % 1131 38.0 % 467 15.7 % 113 3.8 % 0.001 2973 24.0 %
2004–2006 1097 41.1 % 1016 38.0 % 436 16.3 % 122 4.6 % 2671 21.6 %
2007–2009 1309 43.3 % 1094 36.2 % 466 15.4 % 156 5.2 % 3025 24.4 %
2010–2013 1694 45.6 % 1334 35.9 % 504 13.6 % 184 5.0 % 3716 30.0 %
Region
Auckland 4270 44.3 % 3509 36.4 % 1439 14.9 % 412 4.3 % <0.001 9630 77.8 %
Waikato 1092 39.6 % 1066 38.7 % 434 15.8 % 163 5.9 % 2755 22.2 %
Deprivation
1–2 1210 46.4 % 957 36.7 % 353 13.5 % 87 3.3 % <0.001 2607 21.2 %
3–4 963 47.4 % 726 35.8 % 268 13.2 % 73 3.6 % 2030 16.5 %
5–6 1166 44.4 % 985 37.5 % 372 14.2 % 105 4.0 % 2628 21.4 %
7–8 1020 40.8 % 913 36.5 % 429 17.2 % 139 5.6 % 2501 20.4 %
9–10 940 37.5 % 958 38.3 % 440 17.6 % 166 6.6 % 2504 20.4 %
Unknown 63 36 11 5 115 (0.9 %)
Urban rural
Main urban 4064 43.7 % 3421 36.8 % 1417 15.2 % 391 4.2 % <0.001 9293 75.8 %
Other urban 328 45.6 % 262 36.4 % 86 12.0 % 43 6.0 % 719 5.9 %
Rural 901 40.0 % 855 38.0 % 358 15.9 % 136 6.0 % 2250 18.3 %
Unknown 69 37 12 5 123 (1.0 %)
Mode of detection
Screen 3196 67.2 % 1211 25.5 % 296 6.2 % 51 1.1 % <0.001 4754 38.4 %
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Discussion
This study has shown major and significant differences
in stage of breast cancer at diagnosis by ethnicity, socio-
economic status and by urban/rural residency in New
Zealand. We also observed a significant rise in the pro-
portion of metastatic breast cancer although the overall
proportion of advanced breast cancer did not show a
significant change over the 13 year study period.
Differences in rate of advanced or metastatic breast
cancer by ethnicity and socioeconomic status may be
due, in part, to delays in responding to breast symptoms
which may differ between ethnic and socioeconomic
groups. Such differences occur because of differences in
access to care or due to patient factors which include
health literacy, health seeking behaviours or psycho-
social factors [27–29]. Structural organization of the
healthcare system also contributes to these disparities by
forming barriers to access primary health care services
for women of minority ethnicity, low socioeconomic sta-
tus or non-urban residency [30]. For example, a short
supply of primary care physicians has been associated
with late stage of breast cancer at diagnosis [12]. Diffi-
culties in accessing primary care due lack of general
practitioners (GP) especially outside main urban areas,
the costs associated with accessing GPs and barriers due
to services not being culturally safe are well-established
in New Zealand [31, 32]. A relative lack of GPs com-
monly seen in rural and low socioeconomic areas may
lead to patient overload and hence, a lower quality of
care. For instance, if doctors only have a short time to
see patients then they may be less likely to undertake
routine examinations or ask about the presence of breast
lumps. All these factors contribute to a delay and more
advanced cancer stage at diagnosis which leads to poor
cancer outcomes [33].
Improved delivery of primary health care and increas-
ing mammographic breast cancer screening coverage,
as observed in New Zealand over the last two decades
[31], would be expected to have reduced the rate of ad-
vanced and metastatic cancer at diagnosis. In contrast,
the present study observed a steady increase in the pro-
portion of metastatic breast cancer at diagnosis. A similar
scenario is reported from several other developed coun-
tries including the USA, where the rate of metastatic can-
cer has remained static or has steadily increased over the
last two to three decades [34]. This rise has been more
pronounced among women younger than 50 years [35]. It
is unclear whether the observed increase in metastatic
cancer in our study population is an actual increase or an
apparent increase due to several other reasons. For in-
stance, stage migration due to improvements in diagnostic
imaging technology, or increasing use of imaging studies
Table 1 Distribution of selected characteristics by percentage among 12,390 female breast cancer patients diagnosed in New
Zealand during 2000–2013 (Continued)
Non-screen 2166 28.4 % 3364 44.1 % 1577 20.7 % 524 6.9 % 7631 61.6 %
Grade
I 2003 70.1 % 694 24.3 % 134 4.7 % 26 0.9 % <0.001 2857 24.4 %
II 2324 42.7 % 2137 39.2 % 821 15.1 % 167 3.1 % 5449 46.5 %
III 858 25.2 % 1548 45.4 % 820 24.1 % 180 5.3 % 3406 29.1 %
Unknown 177 196 98 202 673 (5.4 %)
ER/PR
ER/PR Positive 4526 46.1 % 3545 36.1 % 1381 14.1 % 373 3.8 % <0.001 9825 81.3 %
ER & PR Negative 716 31.7 % 928 41.0 % 471 20.8 % 146 6.5 % 2261 18.7 %
Unknown 120 102 21 56 299 (2.4 %)
HER-2
Positive 465 29.2 % 576 36.2 % 418 26.3 % 132 8.3 % <0.001 1591 16.7 %
Equivocal 99 48.5 % 73 35.8 % 27 13.2 % 5 2.5 % 204 2.1 %
Negative 3449 44.7 % 2861 37.0 % 1110 14.4 % 302 3.9 % 7722 81.1 %
Unknown 1349 1065 318 136 2868 (23.2 %)
Histology
Ductal 4378 44.2 % 3644 36.8 % 1476 14.9 % 409 4.1 % <0.001 9907 81.3 %
Lobular 480 34.3 % 570 40.7 % 281 20.1 % 68 4.9 % 1399 11.5 %
Mixed 19 26.8 % 30 42.3 % 21 29.6 % 1 1.4 % 71 0.6 %
Other 450 55.9 % 255 31.7 % 62 7.7 % 38 4.7 % 805 6.6 %
Unknown 35 76 33 59 203 (1.6 %)
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Table 2 Multivariate analysis for factors associated with advanced and metastatic breast cancer versus early breast cancer at diagnosis, 2000–2013
Characteristic Univariate Adjusted
OR Advanced 95% CI p OR Metastatic 95% CI p OR Advanced 95% CI p OR Metastatic 95% CI p
Age
<40 1.70 1.43–2.02 1.63 1.15–2.31 1.10 0.92–1.32 1.03 0.70–1.50
40–49 Ref 0.000 Ref 0.000 Ref 0.000 Ref 0.021
50–59 0.76 0.67–0.86 0.81 0.62–1.05 1.10 0.96–1.26 1.24 0.93–1.65
60–69 0.59 0.51–0.67 0.78 0.60–1.03 0.90 0.78–1.05 1.19 0.88–1.61
70–79 0.84 0.72–0.98 1.51 1.15–1.99 0.85 0.72–1.00 1.50 1.10–2.04
80+ 0.98 0.83–1.16 1.72 1.29–2.32 0.76 0.63–0.91 0.84 0.59–1.21
Year of diagnosis
2000–2003 Ref 0.068 Ref 0.079 Ref 0.311 Ref 0.042
2004–2006 1.09 0.96–1.24 1.22 0.94–1.59 0.93 0.80–1.08 1.19 0.87–1.64
2007–2009 1.07 0.94–1.21 1.37 1.07–1.76 0.95 0.81–1.12 1.51 1.10–2.07
2010–2013 0.94 0.83–1.06 1.29 1.01–1.65 0.87 0.75–1.02 1.44 1.06–1.96
Region
Auckland Ref 0.004 Ref 0.000 Ref 0.741 Ref 0.903
Waikato 1.16 1.05–1.29 1.43 1.18–1.72 1.03 0.85–1.24 0.98 0.68–1.42
Ethnicity
NZ European Ref Ref Ref Ref
Maori 1.58 1.37–1.82 0.000 2.14 1.68–2.73 0.000 1.27 1.08–1.49 0.004 1.86 1.39–2.49 0.000
Pacific 2.27 1.95–2.65 0.000 3.38 2.64–4.35 0.000 1.72 1.43–2.06 0.000 2.81 2.03–3.87 0.000
Asian 0.96 0.81–1.14 0.639 0.88 0.61–1.26 0.475 0.81 0.67–0.98 0.026 0.90 0.61–1.33 0.609
Other 0.76 0.55–1.04 0.755 1.10 0.64–1.90 0.737 0.87 0.62–1.23 0.426 1.56 0.86–2.83 0.146
Unknown 0.31 0.17–0.60 0.000 0.15 0.02–1.05 0.056 0.37 0.19–0.72 0.003 0.22 0.03–1.63 0.139
Deprivation
1–2 Ref 0.000 Ref 0.000 Ref 0.000 Ref 0.017
3–4 0.99 0.85–1.16 1.08 0.78–1.48 0.96 0.81–1.14 0.84 0.59–1.19
5–6 1.09 0.95–1.26 1.21 0.91–1.63 1.05 0.90–1.23 0.99 0.71–1.36
7–8 1.45 1.26–1.66 1.79 1.36–2.36 1.31 1.12–1.53 1.40 1.02–1.92
9–10 1.57 1.37–1.80 2.18 1.67–2.84 1.28 1.09–1.51 1.40 1.01–1.92











Table 2 Multivariate analysis for factors associated with advanced and metastatic breast cancer versus early breast cancer at diagnosis, 2000–2013 (Continued)
Urban rural
Main urban Ref 0.009 Ref 0.001 Ref 0.981 Ref 0.004
Other urban 0.91 0.74–1.10 1.40 1.01–1.93 1.03 0.83–1.29 2.00 1.37–2.92
Rural 1.16 1.04–1.30 1.48 1.21–1.81 1.01 0.82–1.25 1.22 0.83–1.82
Unknown 0.66 0.40–1.11 0.90 0.37–2.28 0.78 0.15–4.18 0.40 0.01–46.1
Mode of detection
Screen Ref 0.000 Ref 0.000 Ref 0.000 Ref 0.000
Non−screen 4.83 4.28–5.44 8.18 6.13–10.9 3.79 3.33–4.34 6.03 4.41–8.24
ER/PR status
ER/PR Positive Ref 0.000 Ref 0.000 Ref 0.070 Ref 0.620
ER & PR Negative 1.73 1.55–1.92 1.92 1.58–2.34 1.13 0.99–1.28 1.06 0.83–1.36
Unknown 1.60 1.23–2.08 5.45 4.00–7.45 1.50 1.06–2.14 1.12 0.71–1.79
Grade
Grade I Ref 0.000 Ref 0.000 Ref 0.000 Ref 0.000
Grade II 3.73 3.13–4.44 3.88 2.56–5.88 2.85 2.38–3.40 2.72 1.78–4.14
Grade III 7.00 5.88–8.35 7.76 5.12–11.7 4.13 3.30–5.00 3.85 2.47–5.99
Unknown 13.6 10.8–16.9 56.2 36.8–85.7 12.7 9.82–16.4 49.6 31.2–79.1
HER-2 status
Negative Ref 0.000 Ref 0.000 Ref 0.000 Ref 0.000
Equivocal 0.83 0.57–1.22 0.61 0.25–1.49 0.73 0.48–1.10 0.46 0.18–1.19
Positive 2.36 2.10–2.66 2.65 2.13–3.28 1.57 1.38–1.79 1.80 1.41–2.31











for staging over time might have placed patients in a
higher stage group at diagnosis [36]. Stage migration tends
to occur from an adjacent category (e.g., from stage I or
stage III to stage II) and usually from a lower to the next
higher stage category (e.g., stage III to stage IV). In keep-
ing with this, our study also observed a reduction in the
proportion of stage III cancer which was approximately
equal to the increase in rate of metastatic cancer. Regard-
less, the trajectory of the proportion of metastatic breast
cancer predicts a likely increase in the number of women
being diagnosed with metastatic breast cancer in the
future.
Some researchers argue that the lack of a decrease in
rate of metastatic breast cancer observed in many devel-
oped countries is a reflection of the ineffectiveness of
programmes aimed at improving early diagnosis of
breast cancer which include mammographic breast can-
cer screening [34]. However, it is possible that a majority
of these women who are diagnosed with metastatic
breast cancer are the very same women who have poor
access to health care services, and hence fail to be cap-
tured by mammographic screening programmes. As seen
in the present study, only a very small proportion of
cancers among women who are diagnosed through
mammographic screening are metastatic at diagnosis
and the vast majority of metastatic cancers are diag-
nosed in women with symptomatic cancer. Furthermore,
many researchers have estimated that approximately a
half of the reduction in breast cancer mortality observed
in the last two decades in the developed world has
been due to widespread use of mammographic screen-
ing [37, 38]. Therefore it is unlikely that mammo-
graphic screening is ineffective, rather it is the lack of
penetration of these programmes into populations of
deprived women who are likely to gain a greater bene-
fit that limits its effectiveness at population level.
Increasing rate of metastatic cancer poses several chal-
lenges. First, the healthcare system needs to be geared up
to deal with women with metastatic cancer whose numbers
are likely to increase. Many of these women nowadays have
prolonged survivals due to improved treatments [39] which
will further increase the disease burden on the health sys-
tem. In addition to controlling metastatic disease with vari-
ous treatments, these women will also require expanded
services to provide long-term palliative care and psycho-
social support. Second, it is essential to identify the reasons
for the failure of present health strategies to reduce the
rates of advanced and metastatic breast cancer in New
Zealand. Identification of sub-groups of women who are at
risk of being diagnosed with metastatic cancer, as shown in
this study may help develop strategies specifically targeting
these groups to promote early diagnosis.
Potential limitations of this study include use of area
level deprivation as a proxy measure for individual
socioeconomic status and missing data for some of the
included variables. The NZDep2006 has been validated
as an accurate proxy measure for assessment of socio-
economic deprivation for epidemiological studies [40],
although it inherently has a limited precision to predict
individual deprivation. Further, we did not include data
on health insurance status or lifestyle factors (e.g.,
weight or body mass index, physical activity, diet, etc.,)
or BRCA or other genetic panel-type testing that can
influence breast cancer risk and possibly likelihood of
screening in our analyses as these were not available
from the registries. The analysis performed including
only complete dataset yielded very similar results to
the results shown; hence missing data are unlikely to have
affected the reported findings significantly. Strengths of
this study include the completeness of the sample, which
essentially included 100 % of newly diagnosed cancers
over the study period, and the comprehensive nature of
the prospectively collected data from the registries. Hence,
these study findings are likely to be representative of
breast cancer in New Zealand.
In conclusion, this study has shown significant differ-
ences in the proportions of advanced and metastatic
breast cancer at diagnosis by ethnicity, socioeconomic
status and geography. Further, a small but a significant
increase in the proportion of metastatic breast cancer
was observed over time. While ensuring increasing pro-
visions to manage metastatic breast cancer, steps needed
to be instituted to promote early diagnosis to reduce the
rate of metastatic breast cancer at diagnosis. Increasing
breast cancer screening coverage and increasing health
literacy especially among deprived populations who are
at a greater risk of being diagnosed with advanced breast
cancer may help reduce the rate of metastatic breast
cancer at diagnosis and reduce disparities in stage at
diagnosis.
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